(2S,4R)-methyl 4-hydroxypiperidine-2- carboxylate hydrochloride | 1104460-09-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4R)-methyl 4-hydroxypiperidine-2- carboxylate hydrochloride
• 英文别名: methyl 4(R)-hydroxypiperidine-2(R)-carboxylate hydrochloride；Methyl (2R,4R)-4-Hydroxypiperidine-2-carboxylate Hydrochloride；methyl (2R,4R)-4-hydroxypiperidine-2-carboxylate;hydrochloride
• CAS: 1104460-09-4
• 化学式: C₇H₁₃NO₃*ClH
• 分子量: 195.646
• InChiKey: ZZQYALUPYHIFSA-KGZKBUQUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.31
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  58.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S,4R)-methyl 4-hydroxypiperidine-2- carboxylate hydrochloride 、 5-甲氧基-2-硝基-4-((三异丙基甲硅烷基)氧基)苯甲酸 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以64%的产率得到methyl (2S,4R)-4-hydroxy-1-(5-methoxy-2-nitro-4-((triisopropylsilyl)oxy)benzoyl)piperidine-2-carboxylate
  参考文献：
  名称：

  [EN] G-A CROSSLINKING CYTOTOXIC AGENTS
  [FR] AGENTS CYTOTOXIQUES DE RÉTICULATION G-A

  摘要：

  该发明涉及一种化合物，其化学式为(I)：或其盐、溶剂合物、异构体或互变异构体，其中；A是从中选择的一个基团：R1从H和卤素中选择；R2从-CH2-卤素、C1-6烷基和H中选择，R3是H或不存在；或者R2和R3与它们连接的碳原子一起形成环丙基环；SP是一个间隔基团；B是一个多环基团：R11、R12、R13和R14被选择为：(aa) R11、R12、R13和R14中的一个是E，另一个是可选择取代的Ar1基团；或者(ab) R11、R12、R13和R14中的一个是Rx，其中Rx是Ar1-Z1-E或-E1-Z1-Ar1；Ar1是可选择取代的C5-20芳基或C5-10杂环芳基，每个E独立选择自(CH2)j-S(0)2-NR25R26、(CH2)j-S(0)2-0H、CH2CH2[0CH2CH2]WR25和E1；Z1是NR26、C(=0)-0、O或不存在，这些化合物可用作药物，特别是作为抗增殖剂。

  公开号：

  WO2020157491A1
• 作为产物：
  描述：

  methyl 4(R)-hydroxypiperidine-2(R)-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 、 丙酮 为溶剂， 以95%的产率得到(2S,4R)-methyl 4-hydroxypiperidine-2- carboxylate hydrochloride
  参考文献：
  名称：

  Validation of high-affinity binding sites for succinic acid through distinguishable binding of gamma-hydroxybutyric acid receptor-specific NCS 382 antipodes

  摘要：

  Gamma-hydroxybutyric acid (GHB) binding to multiple sites for the tricarboxylic acid cycle intermediate succinic acid (SUC) has been disclosed recently. In order to better characterize these targets, distinguishable binding of GHB receptor-specific NCS 382 antipodes to [H-3]-SUC or [H-3]-GHB labelled sites in rat brain synaptic membranes was explored. Eutomer binding parameters suggest identity of the high-affinity target for SUC with a synaptic GHB receptor subtype. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.083

文献信息

• Heterocyclic compounds and methods for their use
  申请人：NOVARTIS AG

  公开号：US10308628B2

  公开（公告）日：2019-06-04

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to compounds of formula (I), as described herein, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及可用于拮抗血管紧张素 II 2 型（AT2）受体的杂环化合物。更具体地说，本发明涉及本文所述的式(I)化合物、含有它们的组合物及其在治疗或预防与AT2受体功能有关的紊乱或疾病的方法中的用途，这些紊乱或疾病包括神经性疼痛、炎症性疼痛、与神经元超敏性有关的病症、神经传导速度受损、细胞增殖紊乱、与骨吸收和骨形成失衡有关的紊乱以及与神经再生异常有关的紊乱。
• G-A CROSSLINKING CYTOTOXIC AGENTS
  申请人：Femtogenix Limited

  公开号：EP3917924A1

  公开（公告）日：2021-12-08
• HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE
  申请人：NOVARTIS AG

  公开号：US20180057477A1

  公开（公告）日：2018-03-01

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT 2 ) receptor. More particularly the invention relates to compounds of formula (I), as described herein, compositions containing them and their CM use in methods of treating or preventing disorders or diseases associated with AT 2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.